Clinical Summary
Clinical Summary: A Fully Remote Randomized Trial of Transcranial Alternating Current Stimulation for the Acute Treatment of Major Depressive Disorder
Patients with major depressive disorder often wait weeks for antidepressant benefit, and access barriers leave many without timely specialty care. This trial asks whether a fully remote, self-administered transcranial alternating current stimulation approach can deliver faster symptom relief with minimal safety burden.
Design
A triple-blind, fully remote, randomized controlled trial was conducted in the United States.
N
250 evaluable subjects
Population
Adults meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), criteria for MDD, diagnosed by a study clinician, of moderate-severe severity on the Beck Depression Inventory, Second Edition (BDI-II)
Duration
After 1, 2, and 4 weeks of treatment
Key Findings
- The prespecified primary end point was not met in the intent-to-treat analysis: at week 2, mean BDI-II improvement was 16.65 with active treatment and 14.36 with control, for a between-group difference of 2.04 (1-sided P = .056, 95% CI, −0.476 to 4.549).
- Among participants with 100% compliance in the first 14 days, active treatment produced greater BDI-II improvement than control at week 2 (difference: 3.72, P = .005, 95% CI, 1.103 to 6.340).
- In the adherent subgroup, active treatment also separated from control at week 1 and week 4, with BDI-II differences of 3.10 (P = .022) and 4.10 (P = .018), respectively.
- By week 4, the active treatment group had a higher BDI-II responder rate than the control group: 65.08% vs 52.71% (P = .045).
- Females showed greater week 2 benefit with active treatment than control in subgroup analyses, both in intent-to-treat analysis (17.9 vs 14.2; nominal subgroup P=.020) and per-protocol analysis (18.3 vs 13.76; nominal subgroup P=.008); no serious AEs were reported, and only 1 AE (skin discomfort) led to device discontinuation.
Clinical Bottom Line
Fully remote tACS did not achieve statistical significance on the prespecified week 2 intent-to-treat primary end point, but higher adherence was associated with significant symptom advantages over sham and week 4 responder rates favored active treatment. For major depressive disorder, at-home tACS appears low risk and most clinically relevant when patients can reliably complete twice-daily treatment.
Practice Implications
- If considering at-home tACS for major depressive disorder, emphasize adherence from the outset: 85.1% of participants reported twice-daily usage throughout the first 14 days, and the clearest efficacy signal appeared in those with 100% compliance.
- Set expectations that both active and sham groups improved by week 2, so symptom separation may be modest early; reassess over several weeks, as week 4 responder rates were 65.08% with active treatment vs 52.71% with control.
- Discuss the favorable safety profile during shared decision-making: 19 subjects (15.1%) in the active group reported 34 events and 10 subjects (7.8%) in the control group reported 13 events, with no serious AEs and only 1 discontinuation for skin discomfort.
- Concurrent antidepressant treatment does not need to be excluded when using this approach, since 43.7% of the active treatment group and 36.4% of the sham group reported antidepressant use and, within the active treatment group, week 2 outcomes did not differ for those on vs off antidepressant medications (P = .543).
